Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566722 · ClinicalTrials.gov registry record · Phase 3
Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy
A Phase 3 study of Psoriasis, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT00566722 is a Phase 3 study of Psoriasis that has completed, run by Abbott. The registered enrollment target is 152 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT00566722, a Phase 3 study of Psoriasis, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study was to evaluate the safety and efficacy profile of Humira (adalimumab) in patients who had a sub-optimal response to prior systemic therapy. This open-label study was conducted in a patient population of moderate to severe chronic plaque psoriasis patients, which is an approved patient population for adalimumab.
Conditions Studied
Interventions
- BIOLOGICAL adalimumab
Study Locations (20)
New York
- New York University School of Medicine - New York
- Mount Sinai School of Medicine - New York
- Montifiore Medical Center - The Bronx
Texas
- Dermatology Treatment & Research Center, PA Research - Dallas
- Baylor Research Institute - Dallas
- Center for Clinical Studies - Houston
Alberta
- Kirk Barber Research - Calgary
- Stratica Medical - Edmonton
Alabama
- Total Skin and Beauty Dermatology Centers - Birmingham
Arkansas
- Dermatology Research of Arkansas - Little Rock
California
- Therapeutics Clinical Research - San Diego
Florida
- Florida Academic Dermatology Centers - Miami
Georgia
- Peachtree Dermatology Associates - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00566722
The ClinicalTrials.gov registry entry for NCT00566722 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (69% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which adalimumab is the first listed.
NCT00566722 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Texas, Alberta.
Frequently Asked Questions
What is clinical trial NCT00566722 about?
NCT00566722 is a clinical study titled "Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy". The objective of this study was to evaluate the safety and efficacy profile of Humira (adalimumab) in patients who had a sub-optimal response to prior systemic therapy. This open-label study was conducted in a patient population of moderate to severe chronic plaque psoriasis patients, which is an ap...
What is the current status of trial NCT00566722?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2008-01. Estimated completion is 2009-04.
What conditions does trial NCT00566722 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00566722?
The interventions under investigation include: adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00566722?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00566722 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.